News | November 03, 2007

MASS Stent Trial Measures DES, BMS Risk Rates

November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart attack than bare metal stents, according to a late-breaking outcomes trial presented at the American Heart Association’s Scientific Sessions 2007.

The Massachusetts stent (MASS Stent) trial compared death rates between patients who received drug-eluting stents and those who received bare metal stents. They reviewed records of all adults undergoing percutaneous coronary intervention (PCI) with stenting between April 1, 2003 and December 31, 2004 at all acute care non-U.S. governmental hospitals in Massachusetts. Using this criterion, they identified 20,654 patients from a state database with mandatory follow-up after PCI.

“This is the largest study of patients comparing drug-eluting stents and bare metal stents for long-term outcomes in the U.S.,” said Laura Mauri, M.D., principal investigator of the trial and assistant professor of medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, MA.

“It was previously established that drug-eluting stents make it less likely that patients will need repeat procedures within the first year after a stent procedure,” Mauri said. “What we were less certain about before this study was the long-term safety of drug-eluting stents compared to bare metal.”

Mauri adds that this trial has several benefits for addressing this issue. “It is a very large study with long-term follow up, it reflects contemporary U.S. practice – where most patients receive drug-eluting stents – and it includes all patients who were undergoing PCI – not just those who would have qualified for a randomized trial.”

Patients were followed up for at least two years after receiving a stent. Researchers compared the number of deaths, heart attacks, and revascularization procedures (either bypass surgery or another PCI) between the two groups. The adjusted incidence of mortality at two years was 9.4 percent for those with drug-eluting stents and 11.9 percent for those with bare metal stents.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init